US Exchange Filings

bioAffinity Technologies Stockholders Approve Warrant Shares, Future Offerings, and Share Authorization Reduction

bioAffinity Technologies stockholders approved three measures that could support future share issuance, including shares underlying warrants from two 2026 private placements and securities in future private offerings. They also approved a reduction in the company’s authorized common shares, which took effect on November 20.

The votes authorize potential issuances but do not, by themselves, mean the warrant shares have been issued or that a new offering has occurred.

Key details

  • Warrants from the August private placement: Stockholders approved the issuance of up to 1,128,272 common shares upon exercise of warrants issued in the offering that closed August 14.
  • Warrants from the October private placement: They also approved up to 980,072 shares upon exercise of warrants issued in the offering that closed October 8. Together, the two approvals cover up to 2,108,344 shares. For context, 1,166,625 common shares were outstanding on the September 23 voting record date.
  • Potential future private offerings: Stockholders approved the issuance of securities in one or more non-public offerings. No amount, pricing or timing for any such offering was specified.
  • Fewer authorized shares: The company’s authorized common shares fell from 350 million to 200 million. The amendment became effective when filed on November 20. Authorized shares are the maximum the company may issue; this change does not itself reduce shares already outstanding.
  • Adjournment: Stockholders approved allowing the meeting to be adjourned if more time were needed to gather votes. No adjournment was necessary because the other proposals passed.

Vote results

  • The August warrant proposal received 61,862 votes for, 35,286 against and 834 abstentions.
  • The October warrant proposal received 61,180 votes for, 33,081 against and 3,721 abstentions.
  • The future-offering proposal received 50,700 votes for, 28,910 against and 18,372 abstentions.
  • The authorized-share reduction received 319,130 votes for, 149,445 against and 57,191 abstentions.
  • The adjournment proposal received 308,230 votes for, 159,496 against and 58,040 abstentions. There were also 427,784 broker non-votes on each of the first three proposals.

What changes for investors

The authorized-share ceiling is lower, while the approvals provide a path for the company to issue shares if the warrants are exercised or if it pursues qualifying private offerings. Any shares ultimately issued through those routes would increase the common-share count; the approvals alone do not establish how many shares will be issued or when.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.